1 / 53

Hypertension: A Pharmacological Approach

Hypertension: A Pharmacological Approach. Robert J. DiDomenico, Pharm.D. Hypertension. JNC 7 Express. NIH publication No 03-5233. http://www.nhlbi.nih.gov/guidelines/hypertension/express.pdf . May, 2003. Incidence of Reported End-Stage Renal Disease Therapy, 1982-1995. 253*.

les
Télécharger la présentation

Hypertension: A Pharmacological Approach

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Hypertension:A Pharmacological Approach Robert J. DiDomenico, Pharm.D

  2. Hypertension

  3. JNC 7 Express. NIH publication No 03-5233. http://www.nhlbi.nih.gov/guidelines/hypertension/express.pdf. May, 2003.

  4. Incidence of Reported End-Stage Renal Disease Therapy, 1982-1995 253* *Provisional data. Adjusted for age, race, and sex.

  5. Prevalence of Heart Failure,by Age, 1976-80 and 1988-91 1988-91 1976-80

  6. Hypertension & Blood Pressure • Hypertension is a condition in which the blood pressure is persistently higher than normal • Measurement is indirect • Blood pressure is silent • Hypertensive crisis: acute, life threatening rise in blood pressure associated with acute end-organ damage.

  7. Major Cardiovascular Risk Factors Hypertension Smoking Obesity (BMI > 30) Physical inactivity Dyslipidemia Diabetes mellitus Microalbuminuria or GFR < 60ml/min Advanced age Men > 55, women > 65 Family history of premature CV disease Target Organ Disease Heart Left ventricular hypertrophy CAD Angina and/or prior MI Prior coronary revascularization Heart failure Brain Stroke or TIA Chronic renal insufficiency Peripheral arterial disease Retinopathy Risk Stratification NHBPEP Coordinating Committee. The JNC 7 Report. JAMA 2003;289:2560-72.

  8. JNC 7 Treatment RecommendationsInitial Drug Therapy JNC 7 Express. NIH publication No 03-5233. http://www.nhlbi.nih.gov/guidelines/hypertension/express.pdf. May, 2003.

  9. Hypertension • Therapeutic Treatment Options • Diuretics • Beta blockers • ACE inhibitors • Angiotensin II receptor blockers • Calcium channel blockers • Alpha blockers • Centrally acting alpha agonists • Direct vasodilators • Peripheral adrenergic blockers

  10. Hypertension Functional Aspects of the Sympathetic NS Organ Sympathetic Response Heart Increased contractility (beta-1) Increased HR (beta-1) Arterioles Vasoconstriction (skin/viscera) (alpha-1) Vasodilation (skeletal muscle/liver) (beta-2) Lung Bronchodilation (beta-2) Kidney Increased renin (alpha-1, beta-1)

  11. Hypertension • Therapeutic Options: Beta Blockers • Inhibit sympathetic stimulation • Beta-1 receptors  heart • Beta-2 receptors  blood vessels, lungs • Cardioselective vs. Nonselective • Intrinsic sympathomimetic activity (ISA)

  12. Hypertension • Beta Blockers: CV Pharmacodynamics • Reduced heart rate • Reduced force of heart contraction • Reduced cardiac output • Reduced blood pressure • Decreased renin

  13. Hypertension • Beta Blockers: Potential Adverse Effects • Glucose intolerance, masked hypoglycemia • Bradycardia, dizziness • Bronchospasm • Increased triglycerides and decreased HDL • CNS: Depression, fatigue, sleep disturbances • Reduced C.O., exacerbation of heart failure • Impotence • Exercise intolerance

  14. Hypertension • Beta Blockers: Specific Indications • Myocardial Infarction • Congestive Heart Failure • Essential Tremors • Hyperthyroidism • Angina • Supraventricular tachycardias • Perioperative Hypertension • Migraine Headaches Beta blockers are underused!!! Compelling indications

  15. Hypertension • Therapeutic Options: Alpha-Beta Blockers • Work by binding to both alpha-1 and beta-1 and/or beta-2 adrenergic receptors consequently preventing their activation by sympathetic neurotransmitters. • Carvedilol: alpha-1 + beta-1+ beta-2 blockade • Labetalol: alpha-1 + beta-1 + beta-2 blockade

  16. Hypertension

  17. Hypertension • Therapeutic Options: Diuretics • Promote sodium and water excretion at various sites of the nephron • Loop diuretics • Thiazide/Thiazide-like diuretics diuretics • Potassium-sparing diuretics • Carbonic Anhydrase Inhibitors

  18. Hypertension

  19. Hypertension

  20. Hypertension Carbonic anhydrase inhibitors Thiazide diuretics Potassium-sparing diuretics Loop diuretics

  21. Hypertension • Diuretics: Pharmacodynamics • Decreased intravascular (blood) fluid volume • Decreased extravascular (edema) fluid volume • Decreased blood pressure

  22. Hypertension • Diuretics: Potential Adverse Effects • Electrolyte disturbances • potassium, magnesium, sodium, calcium • Hyperglycemia • Hypotension, orthostasis • Lipid abnormalities • Photosensitivity • Ototoxicity • Hyperuricemia, gout flare

  23. Hypertension • Diuretics: Compelling Indications* • Isolated Systolic Hypertension • Congestive Heart Failure • Diuretics: Possible Favorable Effects • Osteoporosis (thiazides) • Diuretics: Possible Unfavorable Effects • Diabetes • Gout • Renal Insufficiency  Unless contraindicated

  24. Hypertension • Diuretics: Considerations • Useful for patients with ISH, African Americans, CHF • Different diuretic classes can be combined for additive, or possible synergistic effects • Work well in combination with other antihypertensives • Efficacy drops when renal function becomes seriously impaired

  25. Hypertension • Therapeutic Options: ACE Inhibitors • ACE inhibitors inhibit the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor • Therapeutic Options: Angiotensin II Receptor Blockers (ARB’s) • ARB’s block the effects of angiotensin II by competing for binding sites at the receptor

  26. Hypertension Low Blood Pressure Angiotensinogen (liver) bradykinin Renin (kidney) Angiotensin I ACE inhibitor site of action ACE Vasoconstriction +  PVR Aldosterone  Na retention Angiotensin II ARB site of action Angiotensin II receptors Blood Pressure

  27. X X Aldosterone secretion ARB Vasoconstriction X Renal tubular reabsorption of sodium and water X AT1 receptors Catecholamine secretion X Antidiuretic hormone (vasoprressin)secretion X Stimulation of thirst center  BP Hypertension Renin Angiotensinogen Angiotensin I Non-ACE alternate pathways (eg, chymase) ACE Angiotensin II

  28. Hypertension

  29. Hypertension • ACE inhibitors and ARB’s: Pharmacodynamics • Vasodilation • Reduced peripheral resistance • Increased diuresis • Reduced BP • No change in HR • No reduction in cardiac output

  30. Hypertension • ACE Inhibitors/ARB’s: Potential Adverse Effects • ACE inhibitors • Hyperkalemia • Cough • Hypotension, dizziness • Headache • Angioedema • ARB’s • Same as ACE inhibitors but cough is uncommon

  31. Hypertension • ACE inhibitors and ARB’s: Potential Drug Interactions • Medications which promote hyperkalemia • Medications that have activity which is sensitive to changes in serum K+ • Medications that may cause additive antihypertensive effects • NSAIDs

  32. Hypertension • Therapeutic Options: ACE inhibitors • Compelling Indications • Diabetes Mellitus (Type 1) with proteinuria • Heart Failure • Post MI with systolic dysfunction • Possible Favorable Effects • Diabetes Mellitus (Type 1 or 2) with proteinuria • Renal Insufficiency

  33. Hypertension • ACE inhibitors/ARB’s should be carefully considered: • Pre-existing kidney dysfunction (degree of impairment, response to therapy) • Renal artery stenosis (degree of stenosis) • ACE inhibitors/ARB’s are contraindicated: • Pregnancy • History of angioedema • Hyperkalemia

  34. Hypertension • Therapeutic Options: Calcium Channel Blockers (CCB’s) • Calcium channel blockers work by blocking calcium channels through which calcium ions enter muscle fibers, controlling hypertension. • Calcium Channel Blockers • Dihydropyridine • Non-dihydropyridine

  35. Hypertension Calcium Channel Blocking Agents

  36. Hypertension Calcium Channel Blocking Agents

  37. Hypertension • Calcium Channel Blockers: Pharmacodynamics • The activation of calcium channels can increase: • blood pressure by increasing heart rate • stroke volume • cardiac output • total peripheral resistance • Calcium channel blocking reduces these parameters

  38. Hypertension • CCB’s: Potential Side Effects • Dihydropyridines • Peripheral edema • reflex tachycardia • flushing/headache • hypotension • Nondihydropyridines • constipation • conduction abnormalities

  39. Hypertension • Calcium Channel Blockers: Specific Indications • CCB’s: Compelling Indications • Isolated Systolic Hypertension (long-acting) • CCB’s: Possible Favorable Effects • angina • atrial tachyarhythmias • Cyclosporine-induced HTN • Diabetes Mellitus Type 1 and 2 with proteinuria

  40. Hypertension: The Diagnosis and Treatment Process

  41. JNC 7 Express. NIH publication No 03-5233. http://www.nhlbi.nih.gov/guidelines/hypertension/express.pdf. May, 2003.

  42. Why the More Aggressive BP Classifications?High-Normal BP as CV Risk Factor Vasan RS, et al. N Eng J Med 2001;345:1291-7.

  43. Outcomes Studies in High-Risk PatientsALLHAT Study: Optimal 1st Line Agent ALLHAT Investigators. JAMA 2002;288:2981-7.

  44. Outcomes Studies in High-Risk PatientsHOPE Study: Ramipril vs Placebo HOPE Investigators. N Eng J Med 2000;342:145-53.

  45. Outcomes Studies in High-Risk PatientsLIFE Study: Losartan vs Atenolol LIFE Investigators. Lancet 2002;359:995-1003.

  46. Outcomes Studies in High-Risk PatientsEUROPA Study: Perindopril vs Placebo EUROPA Investigators. Lancet 2003;362:782-8.

  47. Algorithm for Treatment of HTN NHBPEP Coordinating Committee. The JNC 7 Report. JAMA 2003;289:2560-72.

  48. Hypertension Treatment CostsPatient Perspective * Most patients require ~ 2 antihypertensive drugs ALLHAT Investigators. JAMA 2002;288:2981-7. www.walgreens.com. Accessed 4/8/05

  49. Algorithm for Treatment (continued) Initial Drug Choices Not at Goal Blood Pressure (< 140/90 mm Hg) No response or troublesome side effects Inadequate response but well tolerated Substitute drug from different class Add second agent from different class(diuretic if not already used)

More Related